Christopher A. Chamberlain

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

Rikke Andersen, Troels Holz Borch, Arianna Draghi et al. · Annals of Oncology · 2018 · 75 citations · Full text

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

Christopher A. Chamberlain, Eric Bennett, Anders Kverneland et al. · Molecular Therapy — Oncolytics · 2022 · 64 citations · Full text

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Anders Kverneland, Christopher A. Chamberlain, Troels Holz Borch et al. · Journal for ImmunoTherapy of Cancer · 2021 · 61 citations · Full text

Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs

Arianna Draghi, Troels Holz Borch, Haja Dominike Radic et al. · International Journal of Cancer · 2018 · 47 citations · Full text

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)

Inna M. Chen, Marco Donia, Christopher A. Chamberlain et al. · European Journal of Cancer · 2022 · 30 citations · Full text